Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease
New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease
New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease
Submitted by
admin
on October 10, 2018 - 10:13am
Source:
CP Wire
News Tags:
Jardiance
Boehringer Ingelheim
Eli Lilly
diabetes
type 2 diabetes
Headline:
New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease
snippet:
Empagliflozin was estimated to extend life expectancy by 1 to 4.
5 years on average
In Sept of 2018 it was announced that the class of drugs that includes empagliflozin was associated with increased risk of necrotizing fasciitis of the perineum
Do Not Allow Advertisers to Use My Personal information
